DSc – Sr. Advisor, Development

Rick is a highly-regarded expert in anti-infectives and held senior preclinical leadership roles during his tenure at Cubist Pharmaceuticals.  Most notably, Rick was responsible for in-licensing the blockbuster Cubicin (daptomycin) from Eli Lilly. 

Specifically, Rick brings valuable expertise in toxicology to guide Peptilogics drug development and preclinical activities. Rick received his PhD in Physiology and Radiation Biology from Harvard University School of Public Health and a BS in Biochemistry from Princeton University.

​

​

​

​

​

​